A Form 4 filed on August 12, 2026, discloses that John Dietrich Pauls, President and CEO of DiaMedica Therapeutics Inc. (NASDAQ:DMAC), acquired 60,200 restricted stock units on August 10, 2026, at a price of $0.

Key Highlights

  • Grant date: August 10, 2026, with 60,200 restricted stock units acquired at $0.
  • Vesting schedule: Units vest in four equal installments on the first, second, third, and fourth anniversaries of the grant date, subject to continued service.
  • Post-transaction ownership: Pauls beneficially owns 128,791 voting common shares following the reported transaction.
  • Deferred share units included: The 128,791 total includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
  • Reporting person role: Pauls is identified as both a Director and Officer (President and CEO) of the issuer.

RSU Grant Details for DiaMedica Therapeutics President and CEO

According to the filing, John Dietrich Pauls, serving as President and CEO and also as a Director of DiaMedica Therapeutics Inc., received 60,200 restricted stock units on August 10, 2026. The transaction is coded as an acquisition (Code A) in Table I of the Form 4, with a reported price of $0 per unit. The filing was signed by Joshua L. Colburn as attorney-in-fact on August 12, 2026.

The filing states that the restricted stock units "will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date." No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, Pauls holds 128,791 voting common shares in direct ownership. The filing notes that this total includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. The shares are described as voting common shares with no par value per share.

What Was Disclosed

The Form 4 discloses a grant of 60,200 restricted stock units to DiaMedica Therapeutics' President and CEO on August 10, 2026, at no cost, with four-year ratable vesting. Post-transaction beneficial ownership stands at 128,791 voting common shares, including 1,749 deferred share units.